Remission clone in acute myeloid leukemia shows growth advantage after chemotherapy but is distinct from leukemic clone.

•A population with the same set of mutations was found in sequential remissions in the bone marrow of a patient with AML.•This “remission clone” contained mutations in NDC80, RBM5, GAS2L3, NR2C2, and SF3B2.•At relapse, the contribution of the remission clone to the myeloid lineage was markedly reduced.•NR2C2-A93V transfected into HEK-293 cells caused a significant increase in viability.